Onena Medicines
Onena Medicines is a biotechnology company founded in 2019, specializing in AI-driven antibody drug discovery for cancer and rare diseases. Headquartered in Basel, Switzerland, with an R&D center in San Sebastian, Spain, the company aims to develop first-in-class DSIP neutralizing antibodies to advance into clinical trials within the next few years.
Company Overview
Onena Medicines is a biotechnology company founded in 2019, specializing in the discovery and development of novel biopharmaceuticals aimed at treating cancer and rare diseases. The company operates with a small team of 11 employees and is headquartered in Basel, Switzerland, with an R&D center located in San Sebastian, Spain. Onena Medicines is a spinout from Stanford University in California, leveraging advanced technologies to innovate in the field of drug discovery.
AI-Centric Drug Discovery Platform
Onena Medicines has developed a proprietary AI-centric antibody drug discovery platform that enables the generation of anti-DSIP neutralizing antibodies without requiring a crystal structure of the antigen. This platform connects artificial intelligence with functional DSIP neutralization, streamlining the drug discovery process to quickly and cost-effectively identify optimal anti-DSIP antibody drugs.
Research and Development Focus
The company utilizes state-of-the-art single cell technologies to investigate the mechanisms behind the failure of current drugs in curing breast cancer. Onena Medicines aims to deliver a pipeline of first-in-class DSIP neutralizing molecules to the clinic within the next few years, focusing on the unique DSIP profiles secreted by different cancer types. The lead candidate, OMED-101, has demonstrated broad efficacy against various cancers in preclinical models.
Specialties and Areas of Expertise
Onena Medicines specializes in several key areas, including oncology, antibody engineering, rare diseases, and biologics. The company is involved in drug discovery and development, clinical trials, and assay development. Its innovative approach targets the neutralization of DSIPs, which are implicated in the uncontrolled growth of diseased cells, thereby restoring normal tissue function.
Future Plans and Vision
Onena Medicines plans to advance multiple neutralizing DSIP antibody drugs into clinical development within the next three years. The company draws strength from diversity and aims to achieve a Silicon Valley vision with Swiss execution and European thoughtfulness, positioning itself as a leader in the biotechnology sector focused on innovative treatments for cancer and rare diseases.